A study looking at the long term effects of treatment for children and adults who have had Wilms' tumour that had spread to their lungs (LEG 2004 06)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Status:
Phase:
This study is looking at the long term effects of radiotherapy and chemotherapy for children and adults with Wilms’ tumour.
Wilms’ tumour is a type of kidney cancer that mainly affects children and some adults (although this is rare). Fortunately, most people are cured. Wilms’ tumour is usually treated with surgery, chemotherapy and sometimes radiotherapy. If the cancer is advanced and has spread to their lungs, children and adults will have chemotherapy with or without radiotherapy to their lungs.
As more people get better from their Wilms’ tumour, researchers are now looking at the long term effects of the treatment you have had. They are trying to find out if radiotherapy to the lungs and, or chemotherapy may have affected the way your lungs now work.
There is a possibility that these treatments may lead to later problems with general health, ability to exercise and risk of developing other medical illnesses or conditions in the future. But doctors are not definitely sure if this happens or to what degree.
The information collected in this study will help doctors to improve the way they follow your progress after their treatment. For example, it may influence the way outpatient appointments and tests are arranged for future patients.
The results of this study may also help doctors to improve future treatment for Wilms’ tumour, while also reducing the side effects.
Who can enter
You can enter this trial if you
- Had Wilms’ tumour affecting one or both of your kidneys and you were treated according to the UK Wilms’ tumour Study Trials 1, 2 or 3 (UK W1-3) treatment regime (your doctor will be able to tell you if this applies to) and had whole lung radiotherapy, with or without abdominal radiotherapy OR
- Had Wilms’ tumour with lung metastases, had treatment according to the UKW1-3 treatment regime and did not have lung radiotherapy (your doctor will be able to tell you if this applies to you)
- Finished treatment at least 2 years ago
You cannot enter this trial if you
- Have had treatment for Wilms’ tumour in the last 2 years
- Are unable to have a lung function tes
Trial design
If you take part, you will be asked to go to hospital for an outpatient appointment. You will then have some tests to find at how well your lungs are working.
You will be asked to breathe and blow into the mouthpiece of a machine. This takes different measurements of your lung function. You will also have a little probe placed on your finger for a minute or so. This measures the level of oxygen in your blood stream.
You will also be asked to complete a written questionnaire. This will ask you about your exercise during an average week. For example, what exercise you do, how often and whether this is influenced by poor health, physical disability or lack of time.
The questionnaire will also ask you about your health and whether you have any chest symptoms. For example, shortness of breath, chest infections and conditions like asthma.
The questionnaire will take you about 10 minutes to complete.
Hospital visits
Taking part in this study will involve one hospital visit. This may be the hospital where you originally had your treatment.
Side effects
This study does not involve a treatment and so there are no side effects associated with taking part.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Gill Levitt
Dr Meriel Jenney
Dr Antony Ng
Supported by
Children's Cancer and Leukaemia Group (CCLG)
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University Hospitals Bristol NHS Foundation Trust
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
